Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma

Junna Oba*, Takeshi Nakahara, Sayaka Hayashida, Makiko Kido, Lining Xie, Masakazu Takahara, Hiroshi Uchi, Shogo Miyazaki, Takeru Abe, Akihito Hagihara, Yoichi Moroi, Masutaka Furue

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    29 Citations (Scopus)

    Abstract

    Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

    Original languageEnglish
    Pages (from-to)1152-1160
    Number of pages9
    JournalJournal of the American Academy of Dermatology
    Volume65
    Issue number6
    DOIs
    Publication statusPublished - 2011 Dec

    Keywords

    • Breslow thickness
    • CD10
    • immunohistochemistry
    • malignant melanoma
    • melanoma-specific survival
    • prognosis
    • tumor progression

    ASJC Scopus subject areas

    • Dermatology

    Fingerprint

    Dive into the research topics of 'Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma'. Together they form a unique fingerprint.

    Cite this